기관회원 [로그인]
소속기관에서 받은 아이디, 비밀번호를 입력해 주세요.
개인회원 [로그인]

비회원 구매시 입력하신 핸드폰번호를 입력해 주세요.
본인 인증 후 구매내역을 확인하실 수 있습니다.

회원가입
서지반출
낮은 복제수 플라스미드를 활용한 일본뇌염바이러스 SA14-14-2주의 Full-Length cDNA 클론의 제작 및 안정적 유지
[STEP1]서지반출 형식 선택
파일형식
@
서지도구
SNS
기타
[STEP2]서지반출 정보 선택
  • 제목
  • URL
돌아가기
확인
취소
  • 낮은 복제수 플라스미드를 활용한 일본뇌염바이러스 SA14-14-2주의 Full-Length cDNA 클론의 제작 및 안정적 유지
저자명
민경일,김영민,추미성,백선영,김재옥,류승렬,민복순,김연희,박미경,변우현,허숙진,Min. Kyung-Il,Kim. Young-Min,Choo. Mi-Sung,Baek. Sun-Young,Kim. Jae-Ok,Ryu. Seung-Re
간행물명
Journal of bacteriology and virology : JBV
권/호정보
2004년|34권 4호|pp.339-353 (15 pages)
발행정보
대한미생물학회
파일정보
정기간행물|
PDF텍스트
주제분야
기타
이 논문은 한국과학기술정보연구원과 논문 연계를 통해 무료로 제공되는 원문입니다.
서지반출

기타언어초록

Recently the reverse genetics system contributed to the progresses in the investigation of positive-stranded RNA viruses. Here, we report the successful construction of a stable full-length infectious cDNA clone of the live attenuated JEV vaccine strain SA14-14-2. The eleven kilobase viral RNA genome was reverse transcribed, amplified as four overlapping DNA fragments and successively ligated into the low copy number plasmid pACYC184, which contains the pl5A origin of replication. In vitro-transcribed RNAs had a specific infectivity of approximately $10^4;PFU/{mu}g$ RNA, and the resulting virus exhibited growth kinetics and plaque morphology similar to the parental virus in cell culture. The structural and functional integrity of the cDNA clone was stably maintained even after at least 150 generations in Escherichia coli strain TOP10. The cDNA clone was engineered to contain single nucleotide change to create a XhoI site and knock out a XbaI site (A to C at nt 9134) acting as a genetic marker. This genetic marker was retained in the recovered progeny virus. Our results suggest that the instability of the full-length infectious JEV cDNA clone can be overcome by employing low copy number plasmid pACYC184. This infectious JEV cDNA clone will aid future studies of pathogenesis, virulence, and replication. Furthermore, it will facilitate the development of SA14-14-2 based recombinant vaccines.